Gilead Sciences has been a dream stock for long-term investors. Anyone who was smart enough to get in at the IPO in 1992 and hold the stock until today are sitting on a gain of around 17,000%! That kind of performance is simply …
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced its intention to offer, …
Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run into some unforseen safety issues with a hep-C candidate called INX-189. Gilead’s rival treatment is a …
One part of the market has held on, another part seems to be falling apart. Over the last month or so the S&P 500 and Dow Jones Industrials have essentially moved sideways, but the Nasdaq and Russell 2000 have clearly trended lower. Tech …
It was a busy week as well as weekend for the biotech sector. Highlights from last week include the approval of Gilead’s (GILD) hepatitis C virus (:HCV) treatment, Sovaldi, and that of Auxilium’s (AUXL) Xiaflex (Peyronie’s disease), a …
Following concerns over Gilead’s 2015 product sales guidance ($26-$27 billion versus $28 billion consensus), Deutsche Bank analysts suggested HCV discounts could be primarily to blame. According to the report, “discounts assume a …